 Randomized, placebo-controlled, partially blinded phase 2 pilot study. Multicenter study approximately 50 centers in approximately 9 countries. Proposed start date is December 2008. The study duration per patient is estimated to be 90 days. Overall study duration is estimated to be 12-18 months. 